丁苯肽联合瑞舒伐他汀对急性缺血性脑卒中患者神经功能的影响  

Effect of Butylphthalide combined with Rosuvastatin on neurologic function in patients with acute ischemic stroke

作　　者：蒋烽烽[1] 鲍翔[1] 刘晓波[1] 徐渭 余丹枫 童民锋[1] 周格知[1] JIANG Fengfeng;BAO Xiang;LIU Xiaobo;XU Wei;YU Danfeng;TONG Minfeng;ZHOU Gezhi(Department of Neurosurgery,Jinhua Central Hospital,Jinhua,Zhejiang 321017,China)

机构地区：[1]浙江省金华市中心医院神经外科,321017

出　　处：《重庆医学》2020年第10期1580-1584,共5页Chongqing medicine

基　　金：2018年浙江省基础公益项目(LGP18H090013)。

摘　　要：目的研究丁苯肽联合瑞舒伐他汀对急性缺血性脑卒中患者的治疗效果及对神经功能的影响。方法选取2016年3月至2019年3月在该院就诊的急性缺血性脑卒中患者126例,根据治疗方式的不同分为丁苯酞组、瑞舒伐他汀组、联合组,各42例。丁苯酞组在基础治疗上给予丁苯肽胶囊治疗,瑞舒伐他汀组给予瑞舒伐他汀片治疗,联合组给予丁苯肽胶囊联合瑞舒伐他汀片治疗。采用美国国立卫生研究院卒中量表(NIHSS)评估患者神经功能,检测血栓素A2(TXA2)、前列环素(PGI2)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)水平,统计不良反应发生率。结果联合组治疗后NIHSS评分低于丁苯肽组、瑞舒伐他汀组(P<0.05)。联合组治疗后TC、TG、LDL-C水平低于丁苯肽组、瑞舒伐他汀组,HDL-C水平高于丁苯肽组、瑞舒伐他汀组(P<0.05)。联合组治疗后hs-CRP、IL-6、TNF-α水平低于丁苯肽组、瑞舒伐他汀组,PGI2水平高于丁苯肽组、瑞舒伐他汀组,TXA2水平低于丁苯肽组、瑞舒伐他汀组(P<0.05)。联合组不良反应发生率略高于丁苯肽组、瑞舒伐他汀组,但差异无统计学意义(P>0.05)。结论丁苯肽联合瑞舒伐他汀通过调节TXA2、PGI2水平促进急性缺血性脑卒中患者神经功能恢复,改善患者血脂水平,起到抗炎作用。Objective To study the therapeutic effect of Butylphthalide combined with Rosuvastatin on patients with acute ischemic stroke and its effect on neurological function.Methods A total of 126 patients with acute ischemic stroke who were treated in this hospital from March 2016 to March 2019 were divided into three groups according to different treatment methods:the Butylphthalide group,the Rosuvastatin group and the combined group,with 42 cases each.The Butylphthalide group was treated with Butylphthalide capsule on the basis of basic treatment,the Rosuvastatin group was treated with Rosuvastatin tablet,and the combined group was treated with Butylphthalide capsule and Rosuvastatin tablet.The neurological function of the patients was evaluated by national institutes of health stroke scale(NIHSS),and the levels of thrombin A2(TXA2),prostacyclin(PGI2),triacylglycerol(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),hypersensitive c-reactive protein(hs-CRP),interleukin 6(IL-6),tumor necrosis factorα (TNF-α)were measured,and the incidence of adverse reactions was counted.Results The NIHSS score of the combined group was lower than that of the Butylphthalide group and the Rosuvastatin group after treatment(P<0.05).The levels of TC,TG and LDL-C in the combined group were lower than those in the Butylphenin group and Rosuvastatin group after treatment,and the levels of HDL-C in the combined group were higher than those in the Butylphenin group and Rosuvastatin group after treatment(P<0.05).After treatment,the levels of hs CRP,IL-6 and TNF-αin the combined group were lower than those in the Butylphthalide group and the Rosuvastatin group.After treatment,the level of PGI2 in the combined group was higher than that in the Butylphthalide group and the Rosuvastatin group,and the level of TXA2 was lower than that in the Butylphthalide group and the Rosuvastatin group(P<0.05).The incidence of adverse reactions in the combined group was higher than that in the Buty

关 键 词：瑞舒伐他汀钙 卒中 丁苯肽 NIHSS评分 

分 类 号：R453[医药卫生—治疗学]